Harpoon Therapeutics Inc (NASDAQ:HARP) Receives $23.75 Average PT from Brokerages
Harpoon Therapeutics Inc (NASDAQ:HARP) has been given a consensus rating of “Buy” by the six brokerages that are currently covering the company, MarketBeat reports. Six research analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $22.00.
A number of analysts recently issued reports on the company. Robert W. Baird assumed coverage on Harpoon Therapeutics in a report on Monday, April 22nd. They set an “outperform” rating and a $25.00 price objective on the stock. Zacks Investment Research raised Harpoon Therapeutics from a “hold” rating to a “buy” rating and set a $15.00 price objective on the stock in a report on Friday, August 9th. Finally, Citigroup reissued a “buy” rating and set a $23.00 price objective on shares of Harpoon Therapeutics in a report on Friday, May 24th.
A number of institutional investors and hedge funds have recently modified their holdings of HARP. MPM Asset Management LLC purchased a new stake in Harpoon Therapeutics during the 1st quarter worth about $42,846,000. New Leaf Venture Partners L.L.C. purchased a new stake in Harpoon Therapeutics during the 1st quarter worth about $27,666,000. Sphera Funds Management LTD. purchased a new stake in Harpoon Therapeutics during the 1st quarter worth about $3,133,000. Fosun International Ltd purchased a new stake in shares of Harpoon Therapeutics in the 1st quarter valued at about $3,062,000. Finally, BlackRock Inc. raised its holdings in shares of Harpoon Therapeutics by 216.8% in the 2nd quarter. BlackRock Inc. now owns 294,047 shares of the company’s stock valued at $3,824,000 after acquiring an additional 201,237 shares in the last quarter. 55.08% of the stock is currently owned by institutional investors and hedge funds.
Harpoon Therapeutics (NASDAQ:HARP) last issued its quarterly earnings results on Monday, August 5th. The company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.13. The firm had revenue of $1.06 million for the quarter, compared to analysts’ expectations of $1.22 million. Equities analysts anticipate that Harpoon Therapeutics will post -2.48 earnings per share for the current year.
Harpoon Therapeutics Company Profile
Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer.
Featured Story: How Investors Can Profit from Options Trading
Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.